125 related articles for article (PubMed ID: 15587931)
21. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
22. New antiviral drugs that target herpesvirus helicase primase enzymes.
Kleymann G
Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
[TBL] [Abstract][Full Text] [Related]
23. New anti-HSV therapeutics target the helicase-primase complex.
Crumpacker CS; Schaffer PA
Nat Med; 2002 Apr; 8(4):327-8. PubMed ID: 11927930
[No Abstract] [Full Text] [Related]
24. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
25. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
27. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
28. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
29. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
30. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
[TBL] [Abstract][Full Text] [Related]
31. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
James SH; Prichard MN
Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
[TBL] [Abstract][Full Text] [Related]
32. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
33. Effect of acyclovir on thermal stress-induced herpesvirus reactivation.
Gebhardt BM; Kaufman HE; Hill JM
Curr Eye Res; 2004; 29(2-3):137-44. PubMed ID: 15512960
[TBL] [Abstract][Full Text] [Related]
34. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
35. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
36. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
[TBL] [Abstract][Full Text] [Related]
37. Antiviral Drugs Against Alphaherpesvirus.
Shiraki K
Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
[TBL] [Abstract][Full Text] [Related]
38. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
39. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
40. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
Field HJ; Biswas S
Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
